Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report) has been assigned an average recommendation of “Hold” from the fourteen brokerages that are covering the stock, Marketbeat reports. Thirteen equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $20.25.
FUSN has been the subject of several recent research reports. Jefferies Financial Group reissued a “hold” rating and set a $21.00 price target (up previously from $10.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Leerink Partnrs cut Fusion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 19th. B. Riley cut Fusion Pharmaceuticals from a “buy” rating to a “neutral” rating and lifted their price target for the company from $13.00 to $23.00 in a report on Wednesday, March 20th. Wedbush cut Fusion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $24.00 target price on the stock. in a report on Tuesday, March 19th. Finally, Brookline Capital Management lowered shares of Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 19th.
Get Our Latest Research Report on Fusion Pharmaceuticals
Fusion Pharmaceuticals Price Performance
Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Fusion Pharmaceuticals had a negative return on equity of 48.74% and a negative net margin of 4,136.55%. Analysts forecast that Fusion Pharmaceuticals will post -1.44 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in shares of Fusion Pharmaceuticals in the 1st quarter worth approximately $616,000. Bluefin Capital Management LLC acquired a new position in shares of Fusion Pharmaceuticals in the 1st quarter worth approximately $213,000. Jane Street Group LLC raised its holdings in shares of Fusion Pharmaceuticals by 2,153.4% in the 1st quarter. Jane Street Group LLC now owns 633,932 shares of the company’s stock worth $13,515,000 after purchasing an additional 605,800 shares in the last quarter. California State Teachers Retirement System bought a new stake in Fusion Pharmaceuticals during the first quarter worth approximately $832,000. Finally, KRYGER CAPITAL Ltd bought a new position in shares of Fusion Pharmaceuticals in the first quarter valued at $2,138,000. Institutional investors and hedge funds own 72.85% of the company’s stock.
About Fusion Pharmaceuticals
Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.
See Also
- Five stocks we like better than Fusion Pharmaceuticals
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Trading Stocks: RSI and Why it’s Useful
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Stock Splits, Do They Really Impact Investors?
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Fusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.